EMA Authorised: Trumenba (Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA has authorised Trumenba, a vaccine against meningococcal disease caused by Neisseria meningitidis serogroup B, for use in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• Trumenba (rLP2086)

Snippet

Status: Authorised. Therapeutic area: Meningitis, Meningococcal. MAH: Pfizer Europe MA EEIG. Decision date: 17/12/2025